CNTG Stock Overview
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.12|
|52 Week High||US$10.68|
|52 Week Low||US$1.09|
|1 Month Change||-13.85%|
|3 Month Change||-53.14%|
|1 Year Change||-89.21%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-92.00%|
Recent News & Updates
Centogene GAAP EPS of -€0.28, revenue of €10.32M
Centogene press release (NASDAQ:CNTG): Q1 GAAP EPS of -€0.28. Revenue of €10.32M (+3.4% Y/Y).
|CNTG||US Biotechs||US Market|
Return vs Industry: CNTG underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: CNTG underperformed the US Market which returned -18.2% over the past year.
|CNTG Average Weekly Movement||14.7%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CNTG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CNTG's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Centogene Fundamentals Summary
|CNTG fundamental statistics|
Is CNTG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNTG income statement (TTM)|
|Cost of Revenue||€154.26m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.62|
|Net Profit Margin||-23.02%|
How did CNTG perform over the long term?See historical performance and comparison
Is CNTG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNTG?
Other financial metrics that can be useful for relative valuation.
|What is CNTG's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CNTG's PS Ratio compare to its peers?
|CNTG PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
HARP Harpoon Therapeutics
TTOO T2 Biosystems
CASI CASI Pharmaceuticals
Price-To-Sales vs Peers: CNTG is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (5.7x).
Price to Earnings Ratio vs Industry
How does CNTG's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CNTG is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Biotechs industry average (14x)
Price to Sales Ratio vs Fair Ratio
What is CNTG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.2x|
|Fair PS Ratio||0.2x|
Price-To-Sales vs Fair Ratio: CNTG is expensive based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Share Price vs Fair Value
What is the Fair Price of CNTG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CNTG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CNTG's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Centogene forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTG's revenue is expected to decline over the next 3 years (-72% per year).
High Growth Revenue: CNTG's revenue is forecast to decline over the next 3 years (-72% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTG's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Centogene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNTG is currently unprofitable.
Growing Profit Margin: CNTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNTG is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.
Accelerating Growth: Unable to compare CNTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: CNTG has a negative Return on Equity (-133.53%), as it is currently unprofitable.
Discover strong past performing companies
How is Centogene's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CNTG's short term assets (€71.3M) exceed its short term liabilities (€28.7M).
Long Term Liabilities: CNTG's short term assets (€71.3M) exceed its long term liabilities (€46.6M).
Debt to Equity History and Analysis
Debt Level: CNTG has more cash than its total debt.
Reducing Debt: CNTG's debt to equity ratio has reduced from 243.1% to 77.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNTG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CNTG has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.3% each year
Discover healthy companies
What is Centogene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Centogene Dividend Yield vs Market|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.5%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Centogene)||n/a|
Notable Dividend: Unable to evaluate CNTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNTG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CNTG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kim Stratton (60 yo)
Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board. She served as Interim Chief Executive Officer of Centogene N.V. si...
Experienced Management: CNTG's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: CNTG's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|31 Jan 22||BuyUS$6,237,280||DPE Deutsche Private Equity GmbH||Company||1,672,193||US$3.73|
|31 Jan 22||BuyUS$5,568,998||TVM Capital GmbH||Company||1,493,029||US$3.73|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.7%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Centogene N.V.'s employee growth, exchange listings and data sources
- Name: Centogene N.V.
- Ticker: CNTG
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$30.331m
- Shares outstanding: 27.08m
- Website: https://www.centogene.com
Number of Employees
- Centogene N.V.
- Am Strande 7
- Mecklenburg-Western Pomerania
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CNTG||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Nov 2019|
|39K||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2019|
|39K||MUN (Boerse Muenchen)||Yes||Common Shares||DE||EUR||Nov 2019|
|39K||XTRA (XETRA Trading Platform)||Yes||Common Shares||DE||EUR||Nov 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/05 00:00|
|End of Day Share Price||2022/10/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.